SGP
SpyGlass Pharma, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$28.94
−0.17%Income statement
| Metric | TTM | 2025 |
|---|---|---|
| Revenue | ||
| Total Revenue | — | — |
| Cost of Revenue | 875.7K | 612.0K |
| Gross Profit | (875.7K) | (612.0K) |
| Operating Expenses | ||
| R&D Expense | 34.7M | 28.6M |
| SG&A Expense | 26.8M | 12.2M |
| General & Admin Expense | 8.9M | 12.2M |
| Selling & Marketing Expense | — | — |
| Other Expenses | (216.7K) | — |
| Total Operating Expenses | 61.2M | 40.8M |
| Cost and Expenses | 62.1M | 41.4M |
| Operating Income (EBIT) | (62.1M) | (41.4M) |
| Non-Operating | ||
| Interest Income | 6.1M | 3.1M |
| Interest Expense | — | — |
| Net Interest Income | 6.1M | 3.1M |
| Other Non-Op Income/Expense | 6.1M | 1.6M |
| Non-Operating Income (excl Interest) | (2.7M) | (1.6M) |
| EBT (Pre-Tax Income) | (56.1M) | (39.9M) |
| Income Tax Expense | — | — |
| Bottom Line | ||
| Net Income | (56.1M) | (39.9M) |
| Earnings from Cont. Ops | (56.1M) | (39.9M) |
| Earnings from Discont. Ops | — | — |
| Bottom Line Net Income | (56.1M) | (39.9M) |
| Per Share | ||
| Basic EPS | ($1.66) | ($1.25) |
| Diluted EPS | ($1.66) | ($1.25) |
| Revenue Per Share | $0.00 | $0.00 |
| Shares | ||
| Basic Shares Outstanding | 33.4M | 31.9M |
| Diluted Shares Outstanding | 33.4M | 31.9M |
| Profitability Metrics | ||
| EBITDA | (58.4M) | (39.3M) |
| D&A | 1.0M | 612.0K |
| EBIT | (59.4M) | (39.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026